51. Scleroderma Clinical trials / Disease details

Clinical trials : 525 / Drugs : 565 - (DrugBank : 148) / Drug target genes : 114 - Drug target pathways : 217

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02551042 (ClinicalTrials.gov)	September 2015	17/12/2014	CSL Behring Sclero XIII	A Phase II, Double-blind, Randomized, Placebo-controlled Study to Investigate Pharmacokinetics (PK), Safety and Efficacy of Intravenous Factor XIII Treatment in Patients With Systemic Sclerosis	Systemic Sclerosis	Drug: Fibrogammin®P, coagulation factor XIII concentrate (Human);Drug: 0.9% sodium chloride	University College, London	CSL Behring	Recruiting	18 Years	N/A	Both	26	Phase 2	United Kingdom
2	EUCTR2014-001101-40-GB (EUCTR)	24/02/2015	14/01/2015	Investigation of safety and therapeutic effect of Fibrogammin® in Scleroderma	Sclero XIII: A phase II ,double-blind, randomized, placebo-controlled study to investigate pharmacokinetics (PK), safety and efficacy of intravenous factor XIII treatment in patients with systemic sclerosis - Sclero XIII	Systemic Sclerosis MedDRA version: 17.1;Level: LLT;Classification code 10010759;Term: Connective tissue disorder NOS;System Organ Class: 100000004859 MedDRA version: 17.1;Classification code 10018124;Term: Generalized scleroderma;System Organ Class: 100000004859 ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]	Trade Name: Fibrogammin® 1250 Product Name: Fibrogammin® 1250 INN or Proposed INN: blood coagulation factor XIII	University College London (UCL)	NULL	Not Recruiting			Female: yes Male: yes	26	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no	United Kingdom